JPMorgan Initiates Praxis Precision With Overweight Rating and $700 Target, Implying 182% Upside Analyst sees approvable assets and places stock on Positive Catalyst Watch. Credit: Praxis Precision Medicines Subscribe now Already have an account? Sign in.
